IP Library Granted Patent US 10,434,064
Granted Patent B2
US 10,434,064 · App. 15/315,538 · Granted Oct 8, 2019

Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Inventors: Aleksandar Filip Radovic-Moreno (State College, PA); Richard Kang (Wilmette, IL); Subbarao Nallagatla (Skokie, IL); Christopher C. Mader (Cambridge, MA); Sergei Gryaznov (San Mateo, CA)
Assignee: Exicure, Inc.
A61K9/1271A61K39/00A61K39/0011A61K39/02A61K39/12A61K39/35A61K39/385A61K47/6911B82Y5/00A61K2039/55555A61K2039/55561A61K2121/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,064
App. No.
15/315,538
Granted
Oct 8, 2019
Kind
B2
Abstract

Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

Claims (11)

1. A nanostructure, comprising

a liposomal core having a lipid bilayer, wherein a nucleic acid immune stimulant that stimulates toll like receptors is associated with the lipid bilayer, and oligonucleotides positioned on the exterior of the liposomal core in the form of an oligonucleotide shell, wherein the oligonucleotides comprise CpG-motif containing oligonucleotides and the CpG-motif containing oligonucleotides are B-class CpG oligonucleotides, wherein the oligonucleotides are indirectly linked to the liposomal core through a linker, wherein all of the oligonucleotides have their 5′-termini exposed to the outside surface of the nanostructure, and wherein the linker is cholesterol.

2. The nanostructure of claim 1 , wherein the nanostructure comprises at least 25 oligonucleotides in the shell.

3. The nanostructure of claim 1 , wherein the oligonucleotides are oriented radially outwards from the liposomal core.

4. The nanostructure of claim 1 , wherein the liposomal core is comprised of phospholipids.

5. The nanostructure of claim 4 , wherein the phospholipids are phosphatidylcholines.

6. The nanostructure of claim 1 , wherein the nanostructure is a self-assembling nanostructure.

7. A composition for use in the treatment of disease, comprising the nanostructure of claim 1 .

8. The nanostructure of claim 1 , wherein the oligonucleotide shell is comprised entirely of oligonucleotides.

9. The nanostructure of claim 1 , wherein the oligonucleotides of the oligonucleotide shell have structurally identical oligonucleotides.

10. The nanostructure of claim 1 , wherein the oligonucleotides have at least one phosphorothioate linkage.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2025
From: MIRKIN, CHAD A.; CHERNYAK, NATALIA; NGUYEN, SONBINH T.; BANGA, RESHAM SINGH
To: NORTHWESTERN UNIVERSITY
Reel/Frame 072306/0845 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2024
From: EXICURE, INC.
To: FLASHPOINT THERAPEUTICS, INC.
Reel/Frame 069171/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: RADOVIC-MORENO, ALEKSANDAR FILIP; KANG, RICHARD; NALLAGATLA, SUBBARAO; MADER, CHRISTOPHER C.; GRYAZNOV, SERGEI
To: EXICURE, INC.
Reel/Frame 040991/0843 →
Continuity (2)
Provisional Application 62007528 · Jun 4, 2014
Related Publication 20170157048A1 · Jun 8, 2017